{'output': [['Drug developer', 'ORG', 'Raise', '47.1 pct', 'ECON_INDICATOR'], ['Drug developer', 'ORG', 'Set_To_Open', '$2.84', 'ECON_INDICATOR'], ['Drug developer', 'ORG', 'Biggest_Pct_Loser', 'all U.S.-listed stocks', 'ORG'], ['Drug developer', 'ORG', 'Says', 'discontinue its intepirdine program', 'CONCEPT'], ['Intepirdine', 'PRODUCT', 'Fail', 'mid-stage study', 'CONCEPT'], ['Intepirdine', 'PRODUCT', 'Fail', 'type of dementia', 'CONCEPT'], ['Patients', 'PERSON', 'Given', 'two doses of intepirdine', 'PRODUCT'], ['Patients', 'PERSON', 'Given', 'placebo', 'PRODUCT'], ['Patients', 'PERSON', 'Suffering', 'dementia with Lewy bodies', 'CONCEPT'], ['Company', 'ORG', 'Stop', 'testing its lead drug', 'PRODUCT'], ['Company', 'ORG', 'Fail', 'meet the main goals', 'CONCEPT'], ['Pfizer', 'ORG', 'Abandon', 'research to find new drugs', 'CONCEPT'], ['Pfizer', 'ORG', 'Aimed', 'treating Alzheimer’s and Parkinson’s disease', 'CONCEPT'], ['AXON stock', 'FIN_INSTRUMENT', 'Fallen', '77.9 percent', 'ECON_INDICATOR'], ['Company', 'ORG', 'Announce', 'failed trial', 'EVENT'], ['Company', 'ORG', 'Reporting', 'Akankshita Mukhopadhyay', 'PERSON'], ['Akankshita Mukhopadhyay', 'PERSON', 'in', 'Bengaluru', 'GPE']]}